Mina Cvjetkovic Bosnjak, Zeljko Bibic, Dusan Kuljancic


Introduction: Serotonin syndrome is a rare but potentially life-threatening condition. In most cases, this complication is caused by taking two serotonergic medications simultaneously, leading to excessive serotonin concentration in the body. Selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SNRIs), as well as irreversible monoamine oxidase inhibitors (MAOIs) and their combination with other serotonergic substances, are associated with symptoms of serotonin syndrome.

Case study: A patient who was prescribed sertalin (an SSRI) for a depressive episode suffered fractures in a traffic accident during the treatement and tramado was perescribed for her pain. ince both drugs tend to increase serotonin levels in the body, a complication in the form of serotonin syndrome developed. With timely recognition and treatment, the symptoms of serotonin syndrome resolved without lasting consequences.

Conclusion: Numerous drugs and substances can induce serotonin syndrome, often in combination with antidepressants. Therefore, it is of great importance that doctors are aware of comorbid conditions that necessitate the use of the mentioned drugs in order to prevent serotonin syndrome. If it does occur, adequate and successful treatment is crucial.

Keywords: Serotonin syndrome, risk, treatment, SSRI, SNRI


Serotonin syndrome, risk, treatment, SSRI, SNRI

Full Text:



Fricchione GL, Beach SR, Huffman JC, Bush G, Stern TA. Life-threatening conditions in psychiatry: catatonia, neuroleptic malignant syndrome and serotonin syndrome.In:Stern TA, Fava M, Wilens TE, Rosenbaum JF, eds. Massachusetts General Hospital Comprehensive Clinical Psychiatry. 2nd ed., 2015.

Meehan TJ. Care of the poisoned patient. In: Walas RM, Hockberger RS, Gausche Hill M, eds Rosens Emegency Medicine: Concepts and Clinical Practice. 10th.ed. Philadelphia PA: Elsevier; 2023:chap 135. doi:10.5070/M561051830.

Sporer KA. The Serotonin Syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995;13 (2):94-104. doi: 10.2165/00002018-199513020-00004.

Dunkley EJ, Isbister GK, Sibri HD, Dawson AH,Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. OJM. 2003;96 (9):635-42.doi:10.1093/qjmed/hcg109

Gillman PK. The serotonin syndrome and its treament. J. Psychopharmacol. 1999(Oxford);13(1):100-9.doi:10.1177/026988119901300111.

Tormoehlen LM, Rusyinak DE. Neuroleptic malignant syndrome and serotonin syndrome. Handb Clin Neurol. 2018;157:663-75.doi:10.1016/8978-0-444-64074-1.00039-2

Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615-9.doi:10.1016/S0736-4679(98)00057-2

Houlihan DJ. Serotonin syndrome resulting from coadministration of tramado, venlafaxine and mirtazapine. Ann Pharmacother.2004;38(3):411-3.doi:10.1345/anh.1D344.

Rickli A, Liakoni E, Hoener MC, Liechti ME. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. Br J Pharmacol. 2018;175(3):532-43. doi: 10.1111/bph.14105.

.Frank C. Recognition and treatment of serotonin syndrome. Can Fam Physician. 2008;54(7):988-92.

Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7(5):587-96. doi: 10.1517/14740338.7.5.587.

Chan BSM Graudins A,Whyte IM, Dawson AH, Braitberg G, Duggin GG. Serotonin syndrome resulting from drug interaction. Med J Aust.1998:169(10): 523-5. doi:10.5694/j.1326-5377.1998tb123399.x.

Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). Can Fam Physician. 2018;64(10):720-7.

Scotton WJ, Hill L, Williams AC, Barnes N. Serotonin Synddrome: pathophysiology, clinical features, management and potentional future direction. Int J Tryptophan Res. 2019;12:11786491987395;doi:10.1177/117864691987395.

Arora B, Kannikeswaran N. The Serotonin Syndrom-the need for physicians awareness. Int J Emerg Med. 2010;3(4):373-7,doi:10.1007/s 12245-010-0195-7.

Levin TT, Cortes-Ladino A, Weiss M, Palomba ML. Life-threatening serotonin toxicity due to a citalopra-fluconazol drug interaction:case reports and discussion. Gen Hosp Psychiatry. 2008;30(4):372-7. doi: 10.1016/j.genhosppsych.2008.03.008.

Morarasu BC,Coman AE, Bolonga C, Lionte C, Petris OR,Ceasovschih A et al.Recognition and management of Serotonin Toxidrome in the Emergency Department-case based review. J Pers Med. 2022;12(12):2069. doi:10.3390/jpm12122069.

Malcolm B, Thomas K. Serotonin toxicity of serotonergic psychodelics. Psychopharmacology. 2022;239(6):1881-91. doi:10.1007/s00213-021-05876-x.

Buckley N,Dawson AH, Isbister GK. Serotonin syndrome. BMJ.2014;348:g1626. doi:10.136/bmj.g.1626

Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352 (11):1112-20. doi:10.1056/NEJMRa041867

Iqbal MM, Basil MJ, Kaplan J, Iqbal T. Overview of serotonin syndrome. Ann Clin Psychiatry.2012;24(4):310-8.

Prakash SA. Diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome. Am J Emerg Med. 2021:43;272-3. doi:10.1016/J.AJEM2020.06.046.


  • There are currently no refbacks.

Copyright (c) 2023 Mina Cvjetkovic Bosnjak

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.